News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Global Partners SillaJen, TRANSGENE (ENX:TNG) And TRANSGENE (ENX:TNG) Confirm Clinical Development Plan For Pexa-Vec


3/26/2014 9:53:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BUSAN, South Korea & SAN FRANCISCO & STRASBOURG, France & HONG KONG--(BUSINESS WIRE)--Regulatory News: Transgene SA (Paris:TNG), Lee’s Pharmaceutical (HKEx: 0950) and SillaJen today unveiled their late-stage clinical development plan for Pexa-Vec (JX-594/TG6006) oncolytic immunotherapy. The companies plan to initiate a global Phase 3 study in the first-line treatment of advanced hepatocellular carcinoma (HCC, liver cancer) patients, as well as several additional Phase 1/2 trials in different cancers, both as a single agent and in combination with a variety of other treatments, including immunotherapies such as immune checkpoint inhibitors. In addition, the partners plan to undertake several exploratory trials of intravenous infusion therapy in various tumor types, including renal, breast and soft tissue sarcoma.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES